Advertisement

MONALEESA-2: Final Overall Survival Results With the Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
Posted: 03/11/2022 | By: Matthew Stenger

Question 1 of 5

Updated median progression-free survival in the ribociclib/letrozole (ribociclib) group vs the placebo/letrozole (control) group was:

Choose 1

A
25.3 months vs 16.0 months
B
50.6 months vs 38.9 months
C
39.9 months vs 30.1 months
D
None of the above

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage